Astellas Pharma Inc.
Astellas Pharma Inc. (ALPMY) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ALPMY · as of Jun 9, 2026
Key Statistics
Explore Astellas Pharma Inc. Data
alpmy stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 3 · Buy rate: 66.7%
Competitors & Peers
alpmy competitorsALPMY
BMXXY
CHJTF
GIKLY
GNMSF
ORINYStock Performance
Full HistoryAbout Astellas Pharma Inc.
Astellas Pharma Inc. operates as a global pharmaceutical enterprise, specializing in the research, development, manufacturing, and commercialization of a broad spectrum of medicinal products worldwide…
what is astellas pharma inc. · alpmy stock overview · astellas pharma inc. company profile · who is astellas pharma inc. ceo · alpmy OTC · astellas pharma inc. headquarters · astellas pharma inc. business segments
About Stock Overview & Key Data
Astellas Pharma Inc. (ALPMY) is a Healthcare company in the Drug Manufacturers - General industry, listed on OTC since Dec 29, 2009. As of the latest trading session, ALPMY stock price is $13.49, with a market capitalization of $24.2B. The stock has returned +38.93% over the past 12 months and +1.50% year-to-date.
According to 3 Wall Street analysts, the consensus rating for Astellas Pharma Inc. stock is Buy, with an average 12-month price target of $—. In fiscal year 2026, Astellas Pharma Inc. reported revenue of $2.27T and net income of $309.1B. For detailed data — including Astellas Pharma Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Astellas Pharma Inc. (ALPMY) stock price is $13.49. The stock is traded on OTC under the ticker symbol ALPMY. The 52-week range is $9.11 – $17.35.